He Hong-Xian, Li Ya-Xin, Xiao Ya-Song, Fan Wen-Hui, Xue Hua
Department of Rehabilitation, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
Department of Neurology, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
Front Neurol. 2024 Jul 5;15:1375587. doi: 10.3389/fneur.2024.1375587. eCollection 2024.
Many systematic reviews (SRs) and meta-analysis (MAs) have reported the efficacy of acupuncture treatment for primary trigeminal neuralgia (PTN), but the quality of evidence is unknown and therefore needs to be evaluated comprehensively.
Eight electronic databases were searched from their inception until January 5, 2024. The methodological quality, reporting quality, and risk of bias of the included SRs were assessed by the assessment of multiple systematic reviews 2 (AMSTAR-2), the Risk of Bias in Systematic Reviews (ROBIS) tool, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The quality of evidence for outcome measures was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).
We identified 13 SRs/MAs met inclusion criteria. According to the results of the AMSTAR-2, six were rated as critically low quality and seven as low quality. According to ROBIS assessment, 8 SRs/MAs were classified as low risk, and 5 SRs/MAs were found to be high risk. The PRISMA report still has some reporting deficiencies in aspects such as protocol and registration, search strategy, risk of bias, additional analyzes and funding. According to the GRADE system, no high-quality evidence was found, 1 was of moderate quality, 4 were of low quality, and 8 were of critical low quality.
Based on the evidence collected, acupuncture shows promise as a treatment for PTN patients. However, it is important to note that the included SRs/MAs generally have low methodological quality and evidence quality. Therefore, caution must be exercised when interpreting this conclusion. To enhance future research in this area, it is recommended to adequately report methodological details and adhere to guidelines for conducting SRs/MAs.: https://www.crd.york.ac.uk/prospero/, identifier CRD42024499280.
许多系统评价(SRs)和荟萃分析(MAs)报告了针刺治疗原发性三叉神经痛(PTN)的疗效,但证据质量未知,因此需要全面评估。
检索了8个电子数据库,检索时间从建库至2024年1月5日。采用多重系统评价评估2(AMSTAR-2)、系统评价中的偏倚风险(ROBIS)工具和系统评价与荟萃分析的首选报告项目(PRISMA)对纳入的SRs的方法学质量、报告质量和偏倚风险进行评估。使用推荐分级评估、制定和评价(GRADE)对结局指标的证据质量进行评估。
我们确定了13项符合纳入标准的SRs/MAs。根据AMSTAR-2的结果,6项被评为极低质量,7项为低质量。根据ROBIS评估,8项SRs/MAs被归类为低风险,5项SRs/MAs被发现为高风险。PRISMA报告在方案和注册、检索策略、偏倚风险、额外分析和资金等方面仍存在一些报告缺陷。根据GRADE系统,未发现高质量证据,1项为中等质量,4项为低质量,8项为极低质量。
基于收集到的证据,针刺对PTN患者显示出治疗前景。然而,需要注意的是,纳入的SRs/MAs总体方法学质量和证据质量较低。因此,在解释这一结论时必须谨慎。为加强该领域未来的研究,建议充分报告方法学细节并遵循SRs/MAs的开展指南。:https://www.crd.york.ac.uk/prospero/,标识符CRD42024499280